Malvern company gets FDA approval for injectible drug to treat cellulite

The company plans to delay the launch of the product until next year because of Covid-19's impact on physician offices and consumer spending.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.